Search Results

Randomized, Placebo-Controlled Study of a New Botulinum Toxin Type A for Treatment of Glabellar Lines: Efficacy and Safety

Authors: BRANDT, FREDRIC; SWANSON, NEIL; BAUMANN, LESLIE; HUBER, BARBARA

Source: Dermatologic Surgery, Volume 35, Number 12, December 2009 , pp. 1893-1901(9)

Publisher: Blackwell Publishing

Treatment strategies for juvenile idiopathic arthritis

Authors: Klein, Ariane; Horneff, Gerd

Source: Expert Opinion on Pharmacotherapy, Volume 10, Number 18, December 2009 , pp. 3049-3060(12)

Publisher: Informa Healthcare

Mitochondrial dysfunction, impaired oxidative-reduction activity, degeneration, and death in human neuronal and fetal cells induced by low-level exposure to thimerosal and other metal compounds

Authors: Geier, D. A.; King, P. G.; Geier, M. R.

Source: Toxicological and Environmental Chemistry, Volume 91, Number 4, June 2009 , pp. 735-749(15)

Publisher: Taylor and Francis Ltd

Adalimumab for psoriasis patients who are non-responders to etanercept: open-label prospective evaluation

Authors: Martyn-Simmons, CL; Green, L; Ash, G; Groves, RW; Smith, CH; Barker, JNWN

Source: Journal of the European Academy of Dermatology & Venereology, Volume 23, Number 12, December 2009 , pp. 1394-1397(4)

Publisher: Blackwell Publishing

Editorial [Hot topic: Drug Targeting of Autoimmunity (Guest Editor: Manfred Kunz)]

Author: Kunz, Manfred

Source: Current Drug Discovery Technologies, Volume 6, Number 4, December 2009 , pp. 230-230(1)

Publisher: Bentham Science Publishers

Current Treatment of Psoriasis with Biologics

Author: Kunz, Manfred

Source: Current Drug Discovery Technologies, Volume 6, Number 4, December 2009 , pp. 231-240(10)

Publisher: Bentham Science Publishers

Biologics as Treatment for Systemic Lupus: Great Efforts, Sobering Results, New Challenges

Authors: Schroder, Johann O.; Zeuner, Rainald A.

Source: Current Drug Discovery Technologies, Volume 6, Number 4, December 2009 , pp. 252-255(4)

Publisher: Bentham Science Publishers

Crohn's Targeted Therapy: Myth or Real Goal?

Authors: Schmidt, Klaus J.; Buning, Jurgen; Jankowiak, Carsten; Lehnert, Hendrik; Fellermann, Klaus

Source: Current Drug Discovery Technologies, Volume 6, Number 4, December 2009 , pp. 290-298(9)

Publisher: Bentham Science Publishers

Use of Biologics in Inflammatory Bowel Disease- Short Synopsis

Authors: Sangwaiya, Arvind; Manglam, Vijay; Arnold, Jayantha

Source: The West London Medical Journal, Volume 1, Number 3, October 2009 , pp. 15-31(17)

Publisher: University of Buckingham Press

The relevance of biologics for the treatment of patients with psoriasis

Author: van deKerkhof, PeterC.M.

Source: British Journal of Dermatology, Volume 161, Number 6, December 2009 , pp. 1213-1214(2)

Publisher: Blackwell Publishing

Pharmacokinetics of Biotech Drugs: Peptides, Proteins and Monoclonal Antibodies

Author: Lin, Jiunn H.

Source: Current Drug Metabolism, Volume 10, Number 7, September 2009 , pp. 661-691(31)

Publisher: Bentham Science Publishers

British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009

Authors: Smith, C.H.; Anstey, A.V.; Barker, J.N.W.N.; Burden, A.D.; Chalmers, R.J.G.; Chandler, D.A.; Finlay, A.Y.; Griffiths, C.E.M.; Jackson, K.; McHugh, N.J.; McKenna, K.E.; Reynolds, N.J.; Ormerod, A.D.

Source: British Journal of Dermatology, Volume 161, Number 5, November 2009 , pp. 987-1019(33)

Publisher: Blackwell Publishing

Developing a legislative pathway for biosimilars in the United States

Author: Waxman, Henry A

Source: Journal of Generic Medicines, Volume 6, Number 4, August 2009 , pp. 295-302(8)

Publisher: Palgrave Macmillan

Mergers & Acquisitions update: Changing the strategic paradigm in the global generics market

Author: Karwal, Vijay P

Source: Journal of Generic Medicines, Volume 6, Number 4, August 2009 , pp. 315-322(8)

Publisher: Palgrave Macmillan

Experience with biologics for psoriasis in daily practice: switching is worth a try

Authors: Lecluse, L.L.A.; deGroot, M.; Bos, J.D.; Spuls, P.I.

Source: British Journal of Dermatology, Volume 161, Number 4, October 2009 , pp. 948-951(4)

Publisher: Blackwell Publishing

Is there truly a risk of lymphoma from biologic therapies?

Authors: Dommasch, Erica; Gelfand, JoelM.

Source: Dermatologic Therapy, Volume 22, Number 5, September/October 2009 , pp. 418-430(13)

Publisher: Blackwell Publishing

Long-term efficacy of biologics in the treatment of psoriasis: what do we really know?

Authors: Alwawi, EihabA.; Krulig, Eliana; Gordon, KennethB.

Source: Dermatologic Therapy, Volume 22, Number 5, September/October 2009 , pp. 431-440(10)

Publisher: Blackwell Publishing

Contemporary treatment principles for early rheumatoid arthritis: a consensus statement

Authors: Kiely, Patrick D. W.; Brown, Andrew K.; Edwards, Christopher J.; O'Reilly, David T.; Östör, Andrew J. K.; Quinn, Mark; Taggart, Allister; Taylor, Peter C.; Wakefield, Richard J.; Conaghan, Philip G.

Source: Rheumatology, Volume 48, Number 7, 4 July 2009 , pp. 765-772(8)

Publisher: Oxford University Press

The Use of Biologics for Psoriasis in Asia-Pacific Region

Authors: Tsai, Tsen-Fang; Yeh, Ting-Yu

Source: Current Rheumatology Reviews, Volume 5, Number 3, August 2009 , pp. 149-152(4)

Publisher: Bentham Science Publishers

Selective Chemokine Receptor-Targeted Depletion of Pathological Cells as A Therapeutic Strategy for Inflammatory, Allergic and Autoimmune Diseases

Author: McDonald, John R.

Source: Recent Patents on Inflammation & Allergy Drug Discovery, Volume 3, Number 3, November 2009 , pp. 177-187(11)

Publisher: Bentham Science Publishers